Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
ACAD
#1237
Acadia Pharmaceuticals Inc.
24.5
6
+1.24%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+1.24%
Monatliche Änderung
-6.83%
6 month change
-7.08%
Jahresänderung
+28.05%
Vorheriger Schlusskurs
24.2
6
Open
24.5
6
Bid
Ask
Low
24.5
6
High
24.5
6
Volumen
140
Märkte
Aktien
Gesundheitswesen
ACAD
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
160.05 M
161.2 M
162.23 M
164.77 M
166.79 M
170.49 M
—
Valuation ratios
Enterprise value
8.23 B
3.62 B
2.53 B
4.9 B
2.74 B
4.38 B
13.68 B
Price to earnings ratio
—
—
-12.18
-83.41
13.49
11.61
53.72
Price to sales ratio
—
—
0.01
0.01
3.19
—
—
Price to cash flow ratio
—
—
-0.02
0.3
19.36
41.32
97.09
Price to book ratio
—
—
0.01
0.01
4.17
3.7
7.12
Enterprise value to EBITDA ratio
-29.83
-22.27
-11.29
-61.66
7.43
—
—
Profitability ratios
Return on assets %
0.36
0.24
0.37
0.08
0.19
0.25
0.27
Return on equity %
0.45
0.31
0.54
0.14
0.31
0.32
0.36
Return on invested capital %
2 612.98
927.62
1 116.07
331.41
423.81
-90.92
6.7
Gross margin %
97.69
97.76
98.03
94.27
91.46
91.69
366.81
Operating margin %
64.87
35.2
43.23
10.1
24.1
9.78
39.09
EBITDA margin %
-62.46
-33.53
-43.37
-10.93
38.52
9.36
37.34
Net margin %
63.74
34.67
41.76
8.44
23.64
36.49
139.94
Liquidity ratios
Quick ratio
6.68
6.28
3.95
2.26
2.14
3.43
11.27
Current ratio
6.77
6.43
4.04
2.42
2.38
3.83
12.64
Inventory turnover
1.27
0.91
0.79
1.6
1.24
0.88
0.85
Asset turnover
0.56
0.65
0.8
1.09
0.99
0.78
0.85
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
0.71
0.1
0.95
0.65
0.65
EBIT per share
—
—
-1.38
-0.47
2.18
0.55
0.46
EBITDA per share
—
—
-1.39
-0.48
2.22
0.59
0.59
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
2.58
2.68
4.54
4.82
18.37
Net current asset value per share
—
—
3.14
3.76
5.64
6.25
23.45
Tangible book value per share
—
—
2.48
2.24
3.68
6.58
19.37
Working capital per share
—
—
2.36
2.21
3.27
4.62
15.97
Book value per share
—
—
2.48
2.64
4.4
7.22
22.04
ACADIA Pharmaceuticals Inc
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Nachrichten
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Jefferies hebt Kursziel für Acadia Pharmaceuticals nach Prognose an
Jefferies raises Acadia Pharmaceuticals stock price target on guidance
Wachstumsausblick: Citizens hebt Kursziel für Acadia Pharmaceuticals an
Citizens raises Acadia Pharmaceuticals price target on growth outlook
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2026-02-25
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
ACADIA Q4 2025 slides: $1B revenue milestone as both drugs post double-digit growth
ACADIA übertrifft Gewinnerwartungen für Q4 2025 deutlich, verfehlt aber die Umsatzprognose
Acadia vor Quartalszahlen: Umsatzwachstum erwartet, doch Gewinne unter Druck
Acadia Pharmaceuticals: Wolfe Research startet Coverage mit "Outperform" und Kursziel 33 Dollar